What's Happening?
Researchers at Montefiore Einstein, led by Kira Gritsman, M.D., Ph.D., have identified a potential new treatment strategy for acute myeloid leukemia (AML), an aggressive blood cancer known for its high relapse rate. The team discovered that leukemia stem
cells, which often survive initial treatments and cause the cancer to return, can be targeted by combining two specific drugs. Their research, published in Leukemia, found that blocking the PI3K protein initially encourages leukemia cells to mature and reduces their ability to renew. However, these cells eventually adapt by relying on a backup system involving EZH2 and EZH1 proteins. The researchers then found that inhibiting EZH1 gene expression made the cells more vulnerable to PI3K inhibition. By combining copanlisib, a PI3K blocker, with valemetostat, which blocks both EZH1 and EZH2, they observed a more effective killing of leukemia cells and a reduced ability of leukemia stem cells to restart the disease in mouse studies and patient cell samples.
Why It's Important?
This research offers a significant advancement in the fight against acute myeloid leukemia (AML), a cancer with a high rate of recurrence due to the persistence of leukemia stem cells after treatment. The ability to target these resilient cells could dramatically improve patient outcomes and reduce relapse rates. By understanding and exploiting the cancer cells' adaptive mechanisms, the Montefiore Einstein team has opened a new avenue for therapeutic intervention. This dual-drug approach, which combines existing knowledge of PI3K inhibition with a novel strategy to counter cellular adaptation, could lead to more durable remissions and potentially save lives. The findings are particularly important for patients who currently face limited options once their AML relapses, offering hope for more effective and sustained treatment responses.
What's Next?
The next crucial step for this promising dual-drug strategy is to determine its safety and efficacy in human patients. While the research has shown positive results in mouse models and patient cell samples, clinical trials will be necessary to translate these findings into a viable treatment. Further research will focus on understanding the optimal dosages, potential side effects, and long-term benefits of combining copanlisib and valemetostat. If successful, this approach could lead to new clinical protocols for AML treatment, potentially offering a more robust defense against relapse and improving the overall prognosis for patients battling this aggressive blood cancer. The findings also pave the way for exploring similar adaptive resistance mechanisms in other cancers.
Beyond the Headlines
This research highlights a broader shift in cancer treatment strategies, moving towards understanding and counteracting the adaptive mechanisms that allow cancer cells to survive and proliferate. The concept of targeting a 'backup system' that cancer cells employ when their primary pathways are blocked is a sophisticated approach that could have implications beyond AML. It underscores the complexity of cancer biology and the need for multi-pronged therapeutic interventions. This study also emphasizes the value of basic science research in uncovering fundamental biological processes that can be leveraged for clinical benefit. The ethical considerations for future clinical trials will involve balancing the potential benefits of this aggressive treatment with managing potential side effects, especially given the vulnerability of leukemia patients.
